Substituted isoindole allosteric EGFR inhibitors
US11117890B2 · kind B2 · utility
1Cited by
0References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2019 |
| Grant date | Sep 14, 2021 |
| Priority date | — |
| Expiry date | Dec 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/12
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula: or a pharmaceutically acceptable salt thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.